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Abstract 1 
Aims: To evaluate the effect of the Mediterranean diet (MedDiet) on the incidence of 2 
heart failure (HF), a pre-specified secondary outcome in the PREDIMED 3 
(PREvención con DIeta MEDiterránea) primary nutrition-intervention prevention 4 
trial. 5 
Methods and Results: Participants at high risk of cardiovascular disease (CVD) were 6 
randomly assigned to one of three diets: MedDiet supplemented with extra-virgin 7 
olive oil (EVOO), MedDiet supplemented with nuts, or low-fat control diet. Incident 8 
HF was ascertained by a Committee for Adjudication of events blinded to group 9 
allocation. Among 7403 participants without prevalent HF followed for a median of 10 
4.8 years, we observed 29 new HF cases in the MedDiet with EVOO group, 33 in the 11 
MedDiet with nuts group and 32 in the control group. No significant association with 12 
HF incidence was found for the MedDiet with EVOO and MedDiet with nuts, 13 
compared with the control group [hazard ratio (HR) 0.68; 95% CI, 0.41-1.13 and HR 14 
0.92; 95% CI, 0.56-1.49, respectively].  15 
Conclusion: In this sample of adults at high CVD risk, the MedDiet did not result in 16 
lower HF incidence. However, this pre-specified secondary analysis may have been 17 
underpowered to provide valid conclusions. Further randomised controlled trials with 18 
HF as a primary outcome are needed to better assess the effect of the MedDiet on HF 19 
risk. 20 
 21 
Keywords: Mediterranean diet; heart failure; cardiovascular disease; PREDIMED 22 
study   23 
 5 
Introduction 1 
The prevalence of heart failure (HF) is increasing during the last decades.1 HF is also 2 
the leading cause of hospitalisation in older adults and it is associated with an 3 
enormous burden of disability and healthcare costs.2 This emerging epidemic 4 
represents an insurmountable public health challenge that can compromise the 5 
sustainability of national health systems.1,2  6 
Primary prevention of HF should be a priority.3 Hypertension, obesity and 7 
type 2 diabetes (T2D)4 are strong risk factors not only for HF, but also stroke, 8 
myocardial infarction (MI), atrial fibrillation (AF)5 and peripheral arterial disease 9 
(PAD).6 Multi-morbidity is common in HF and higher cardiovascular (CVD) 10 
mortality is observed when several of these CVD manifestations coexist.7 Therefore, 11 
effective preventive interventions against MI or stroke seem also likely to reduce HF.  12 
In this context, there is increasing evidence that changes in overall dietary 13 
patterns, and, specifically, interventions using the traditional Mediterranean diet 14 
(MedDiet) are a useful tool in CVD prevention.8,9 Two cohort studies reported a lower 15 
HF risk associated with better adherence to MedDiet.10,11 However, no randomised 16 
controlled trial to date has examined the effect of the MedDiet on the primary 17 
prevention of HF. One-year results from the PREvención con DIeta MEDiterránea 18 
(PREDIMED) randomised controlled trial showed that the MedDiet favourably 19 
affected HF biomarkers compared to a low-fat diet.12 In PREDIMED, the MedDiet 20 
also favourably influenced major HF risk factors, such as T2D,13 obesity14 and 21 
hypertension.15 The aim of this study was to investigate with a randomised design the 22 
effect of the MedDiet on HF incidence, a protocol-specified secondary outcome of the 23 
PREDIMED trial.16 We hypothesised that the MedDiet would result in lower HF 24 
incidence, compared to a control, low-fat, diet.  25 
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 26 
Methods 27 
Study design 28 
The detailed methods of this trial (www.predimed.es) have been described.9,16 In 29 
brief, PREDIMED was a large, parallel-group, randomised controlled trial conducted 30 
in 11 centres in Spain, designed to examine the effect of the MedDiet on primary 31 
CVD prevention. The trial was registered (ISRCTN35739639) and conformed with 32 
the principles outlined in the Declaration of Helsinki. The protocol was approved by 33 
the Institutional Review Boards of participating centres and all participants provided 34 
written informed consent to take part in the study. Participants were recruited between 35 
10/2003 and 03/2009 from Spanish primary care centres. The study was planned for 6 36 
years, but was stopped at 4.8 years of median follow-up (12/2010), because of 37 
evidence of early benefit.9 Yearly follow-up measurements continued until 10/2012.  38 
 39 
Participants and randomisation 40 
Participants were men (55-80 years) and women (60-80 years) who were free of CVD 41 
at enrollment but who were at high-CVD-risk, as defined by the presence of T2D 42 
and/or ≥3 CVD risk factors, namely smoking, hypertension, elevated low-density 43 
lipoprotein (LDL) cholesterol, low high-density lipoprotein (HDL) cholesterol, 44 
overweight/obesity (body mass index, BMI≥25kg/m2), or family history of premature 45 
coronary heart disease (CHD). Detailed inclusion and exclusion criteria are provided 46 
elsewhere.9,16  47 
 Participants were randomly assigned to one of three dietary intervention 48 
groups (1:1:1 ratio): (i) MedDiet supplemented with extra-virgin olive oil (EVOO), 49 
(ii) MedDiet supplemented with mixed nuts or (iii) low-fat control diet. 50 
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Randomisation was conducted centrally using a computer-generated random-number 51 
sequence. All clinical investigators, laboratory technicians and members of 52 
Committees assessing clinical events were blinded to intervention allocation.  53 
 54 
Intervention description 55 
The PREDIMED dietary intervention has been detailed elsewhere.9,16 Briefly, all 56 
participants received repeated and continuous advice from trained dietitians to follow 57 
their allocated diets (during both individual and group sessions, separately for each 58 
group) on a quarterly basis.9,16 The diets were ad libitum regarding total energy intake. 59 
Physical activity was assessed but not promoted.  60 
Participants assigned to the MedDiet+EVOO group were provided with 1 litre 61 
of EVOO/week (including family needs), whereas those in the MedDiet+nuts group 62 
received 30 grams/day of mixed nuts. These supplementary foods were given for free 63 
in order to facilitate adherence. Participants in the control group received small non-64 
food gifts.  65 
 66 
Measurements 67 
All measurements were carried out at baseline and yearly and comprised a 47-item 68 
questionnaire assessing sociodemographic characteristics, medical conditions, 69 
medication use and lifestyle habits, a 14-item questionnaire assessing MedDiet 70 
adherence,17 an 137-item FFQ, used to assess nutrient and energy intake,18 and the 71 
Spanish version of the Minnesota Leisure-Time Physical Activity questionnaire.9,16 72 
Trained nurses collected fasting blood samples and measured blood pressure, body 73 
weight, height and waist circumference to calculate waist-to-height ratio (WtHR).  74 
 75 
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Clinical endpoints 76 
The primary outcome for the present study was HF incidence, a protocol-specified 77 
secondary outcome of the PREDIMED trial.16 All HF events were evaluated 78 
according to the 2005 (time of study design) guidelines on the diagnosis and treatment 79 
of acute and chronic HF of the European Society of Cardiology.19,20 The diagnostic 80 
criteria for ascertaining HF events are presented in Supplementary Appendix 1.  81 
All endpoints of the PREDIMED trial, including HF, were identified 82 
prospectively through contacts with participants and family physicians, annual 83 
reviews of all participants’ outpatient and inpatient medical records and linkage to the 84 
National Death Index and were analysed by events. If an HF diagnosis was an explicit 85 
medical diagnosis, all relevant documentation, including clinical records of hospital 86 
discharge, outpatient clinics and family physicians’ records, was sent to the Clinical 87 
Adjudication Committee. This documentation was independently reviewed and 88 
blindly evaluated by two cardiologists. If there was disagreement regarding the 89 
acceptance or rejection of an event, a third cardiologist (the Committee’s Chair) 90 
intervened until agreement was reached (in some cases, more information was 91 
requested to complete the ascertainment). All members of the Clinical Adjudication 92 
Committee and the adjudication process were blinded to group allocation. This paper 93 
reports on HF events that occurred during the trial’s active intervention (10/2003-94 
07/2010).  95 
 96 
Statistical analyses 97 
Cox regression models with robust variance estimators were fitted to estimate Hazard 98 
Ratios (HR) and 95% confidence intervals (CIs) for the incidence of HF by group 99 
assignment (using the control group as reference).  100 
 9 
The assumption of proportional hazards was tested using time-dependent 101 
covariates. We stratified all models by centre and baseline T2D. A crude model was 102 
followed by an age- and sex-adjusted model. We further adjusted for pre-103 
randomisation values of education, smoking, WtHR, physical activity, dyspnea and 104 
non-AF arrhythmias (model 1), and, additionally for history of hypertension, history 105 
of dyslipidaemia, family history of premature CHD and baseline prevalence of AF 106 
(model 2), and additionally for total energy intake (model 3). We evaluated potential 107 
effect modification by sex, age, CVD risk factors, WtHR, and baseline MedDiet 108 
adherence.  109 
Follow-up time was the interval between randomisation and diagnosis, death 110 
or the last visit, whichever occurred first. We defined event rates as the number of 111 
participants diagnosed with an event over the follow-up time in each group.  All 112 
analyses were performed on an intention-to-treat basis. 113 
 114 
Results 115 
After excluding 44 participants with prevalent HF at baseline, 7403 were included in 116 
the present analyses (Supplementary Appendix 2). The three groups were well 117 
balanced regarding baseline characteristics (Table 1).  118 
Ninety-four participants developed HF during the trial period with active 119 
intervention (Table 2). Of these, 19 (20.2%) had preceding ischemic heart disease and 120 
58 (61.7%) were hospitalised. Data on receipt of treatment following HF diagnosis 121 
were available for 79 participants, who received ACE inhibitors/ARA II (74.7%), 122 
diuretics (65.8%), beta-blockers (26.6%), calcium channel blockers (20%), 123 
antiplatelet therapy (29.1%) and oral anticoagulants (25%). Ventricular function 124 
information after HF diagnosis (assessed via echocardiography) was available for 80 125 
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participants, who presented with preserved ejection fraction (>45-50%) (60%) and 126 
reduced ejection fraction (40%). Twenty-one (out of 94) participants (22.3%) died by 127 
2012 (end of extended follow-up).  128 
The baseline characteristics of participants who developed HF during the 129 
active intervention period and those who did not are shown in Supplementary 130 
Appendix 3. Those who developed HF were generally older and had higher WtHR 131 
and B-type natriuretic peptide levels. The unadjusted HR did not indicate significant 132 
associations for the MedDiet+EVOO (HR=0.68; 95% CI, 0.41-1.13) and 133 
MedDiet+nuts (HR=0.92; 95% CI, 0.56-1.49), compared with the control group. 134 
Multivariate analyses did not alter these results (Table 2, Figure 1). There was no 135 
evidence of a significant association for the two MedDiets combined, compared with 136 
the control group, in the unadjusted (HR=0.79; 95% CI, 0.51-1.22) and multivariable-137 
adjusted models (Supplementary Appendix 4).  138 
In subgroup analyses (Supplementary Appendix 5), the effect of the MedDiet 139 
on reducing HF, though statistically not significant, was stronger among participants 140 
without T2D (P for interaction=0.010). A higher baseline WtHR was associated with 141 
a risk reduction related to the MedDiet+nuts and higher baseline MedDiet adherence 142 
was associated with an inverse association of MedDiet+EVOO with HF. In both cases 143 
the P for interaction was significant, but the effect within subgroups was not. 144 
Overall, 141 HF events occurred during the trial period with active 145 
intervention and extended follow-up (Supplementary Appendix 6). The unadjusted 146 
HRs were 0.71 (95% CI, 0.47-1.07) for the MedDiet+EVOO and 0.99 (95% CI, 0.67-147 
1.48) for the MedDiet+nuts, compared with the control diet. Adjusting for different 148 
covariates (Supplementary Appendix 6) and examining the combined effect of the two 149 
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MedDiet groups, compared with the control group (Supplementary Appendix 4), did 150 
not alter these findings.  151 
 152 
Discussion 153 
This secondary analysis of a pre-specified outcome of the PREDIMED trial showed 154 
no evidence of a significant effect on HF incidence for the intervention using a 155 
MedDiet+EVOO or a MedDiet with nuts, compared to the control diet. Our 156 
hypothesis of a beneficial effect of the MedDiet on HF incidence in this sample of 157 
high-CVD-risk individuals was therefore not confirmed for this secondary endpoint of 158 
the trial. However, the explanation for the not significant results for HF might stem 159 
from the relatively small number of observed HF events (n=94) and it should be given 160 
the interpretation that our findings are inconclusive.  161 
To our knowledge, PREDIMED is the first randomised controlled trial in 162 
which the potential effect of an intervention with the traditional MedDiet on primary 163 
HF prevention could be explored (as HF was a secondary, and not a primary outcome 164 
of PREDIMED). An earlier report of the PREDIMED trial showed that the 165 
intervention with the MedDiet reduced the levels of HF biomarkers, including N-166 
terminal pro-brain natriuretic peptide, oxidised LDL-cholesterol and lipoprotein(a).12 167 
Despite this beneficial effect on HF biomarkers,12 as well as on HF risk factors such 168 
as hypertension,15 T2D13 and obesity,14 we may have had here limited statistical 169 
power to demonstrate an effect on the incidence of newly-onset clinical cases of HF 170 
considered alone. Nevertheless, the finding that HF incidence was consistently lower 171 
in the point estimates during the trial for the MedDiet+EVOO, regardless of the 172 
factors we adjusted for (risk reduction range, 22-32%), generates a hypothesis for 173 
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future randomised controlled trials to examine the potential effect of the traditional 174 
MedDiet on HF as a primary outcome, in a sufficiently powered study.  175 
Two recent prospective cohorts with up to 10 years of follow-up reported 176 
inverse associations of the MedDiet with HF incidence and mortality (1648 events) in 177 
men11 and HF incidence (1269 events) in women.10 An exploratory meta-analysis of 178 
prospective cohort studies21,22 conducted for the purposes of the current paper 179 
suggested that, according to previous evidence, for each 2 additional points of 180 
MedDiet adherence (0 to 9 score), the relative risk of HF decreased by 8% (95% CI, 181 
0.90-0.95, without evidence of heterogeneity, I2=0%) (Supplementary Appendix 7). 182 
The difference in the number of observed events and the length of follow-up between 183 
these studies and the PREDIMED randomised trial might explain why our study was 184 
probably not sufficiently powered as to confirm these previous observational findings. 185 
Although the findings of the current study are inconclusive, when they are considered 186 
together with the results from other prospective studies, they may suggest a potential 187 
beneficial role of the MedDiet in HF prevention. The advantage and novelty of 188 
PREDIMED is that our results come from a randomised intervention. Additionally, 189 
the PREDIMED trial started on the basis of a relatively high baseline adherence to the 190 
MedDiet in the three arms of the trial, which might have attenuated the findings. In an 191 
exploratory secondary analysis of the association between participant baseline 192 
characteristics and HF, we found that older age at baseline and T2D history were 193 
significantly associated with higher HF rates, whereas higher baseline MedDiet 194 
adherence (assessed in an observational approach) might have been associated with a 195 
37% (HR=0.63; 95% CI, 0.40-0.98) lower HF rate (Supplementary Appendix 8). It 196 
might be, however, that this high baseline adherence reflected better compliance with 197 
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other lifestyle factors that may have an influence on HF, and residual confounding 198 
cannot be excluded in this observational approach.  199 
Several mechanisms might explain a potential beneficial role of the MedDiet 200 
for HF prevention, as suggested by our exploratory meta-analysis, including the 201 
MedDiet’s anti-inflammatory23 and antioxidant24 properties. Oxidative stress25 and 202 
inflammation26 accompany HF and olive oil, in particular, has been associated with 203 
reduced HF risk.27 Earlier PREDIMED reports showed that biomarkers of 204 
inflammation28 and oxidation12 were reduced with the MedDiet+EVOO compared to 205 
the other two groups. In the current analyses, the difference in the size of the 206 
association with HF incidence between the MedDiet+EVOO and MedDiet+nuts 207 
groups (although both not significant) might have resulted from the fact that 208 
participants in the MedDiet+EVOO group were provided (at no cost) with EVOO 209 
with highly constant content of polyphenols. In contrast, that was not the case for 210 
participants in the MedDiet+nuts group who bought their own oils, with potentially 211 
varied polyphenol content. The anti-inflammatory and antioxidant properties of 212 
EVOO, attributed to its polyphenol content, have been well documented29 and add 213 
biological plausibility to the hypothesis of a protection against HF by a MedDiet high 214 
in EVOO. As results from the current study were inconclusive, this hypothesis should 215 
be studied further by future randomised controlled trials with longer follow-up periods 216 
and sufficient statistical power to examine whether this protective effect exists.  217 
HF shares common risk factors with other cardiovascular conditions and 218 
earlier studies have included HF as part of a composite CVD endpoint. For example, 219 
the Lyon Heart Study showed that a MedDiet reduced the risk of a composite 220 
endpoint that included HF by 67% (RR 0.33; 95% CI, 0.21-0.52).8 A recent 221 
randomised controlled trial, Look AHEAD,30 also included HF in its composite CVD 222 
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endpoint. An exploratory secondary analysis of our data that examined the effect of 223 
the MedDiet on a composite outcome of 634 observed total CVD events (i.e. MI, 224 
stroke, CVD death, HF, AF or PAD) showed that the unadjusted HRs were 0.62 (95% 225 
CI, 0.51-0.75) for the MedDiet+EVOO and 0.77 (95% CI, 0.63-0.93) for the 226 
MedDiet+nuts, compared to the control diet (Supplementary Appendix 9; 227 
Supplementary Appendix 10). Although this specific exploratory analysis might be 228 
prone to bias, as it was not a pre-specified outcome of the PREDIMED trial, it might 229 
allow useful comparisons with existing or future studies examining the effect of the 230 
MedDiet on composite CVD outcomes that include HF.  231 
Our study also has limitations. HF was a pre-specified secondary endpoint of 232 
the PREDIMED trial, and the trial was probably underpowered, taking into account 233 
the small number of observed HF events. Further, HF is a syndrome with various 234 
clinical etiologies and symptoms, as well as definitions,19,20,31 and the effect of dietary 235 
patterns might differ according to the type, severity and pathogenesis of the 236 
condition.1,2 We could not determine HF etiology or severity in PREDIMED and the 237 
possibility of some degree of HF misclassification may exist. In addition, we used the 238 
2005 HF guidelines to adjudicate HF events, concomitant with the time of the 239 
PREDIMED trial’s design.16 Nevertheless, our HF diagnostic criteria are in agreement 240 
with the recently published American College of Cardiology/American Heart 241 
Association clinical data standards, where ‘HF can be diagnosed when a patient 242 
demonstrates or there is objective evidence of new or worsening HF symptoms and 243 
receives HF-specific treatment, with objective evidence results from at least two 244 
physical examination findings’.31 In any case, the use of specific criteria to adjudicate 245 
events and the adjudication by an independent Committee in the context of a large and 246 
well-known randomised trial reduce the potential for misclassification. Finally, our 247 
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results are not generalisable to other populations (e.g. non-Mediterranean countries, 248 
younger adults or adults without CVD risk).  249 
In conclusion, we were not able to show that an intervention with MedDiet 250 
reduced the risk of clinical cases of HF. However, this pre-specified secondary 251 
analysis of the PREDIMED trial may have been underpowered to provide valid 252 
conclusions. Further randomised controlled studies with HF as a primary endpoint are 253 
needed to better assess the specific effect of the traditional MedDiet on HF risk. 254 
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Table 1 Baseline characteristics of participants by intervention group 452 
  Mediterranean 
diet+EVOO (n=2527) 
Mediterranean 
diet+nuts (n=2444) 
Control diet 
(n=2432) 
Age, years 67.0 (6.2) 66.7 (6.1) 67.3 (6.3) 
Sex, female, n (%) 1484 (58.7) 1319 (54.0) 1455 (59.8) 
Smoking, n (%) 
      Current 346 (13.7) 354 (14.5) 338 (13.9) 
Education, n (%) 
      University or higher 
      Secondary school 
      Primary school 
      No education 
186 (7.4) 
370 (14.6) 
1851 (73.2) 
120 (4.8) 
201 (8.2) 
412 (16.9) 
1733 (70.9) 
98 (4.0) 
144 (5.9) 
334 (13.7) 
1853 (76.2) 
101 (4.2) 
Waist-to-height ratio 0.63 (0.06) 0.63 (0.06) 0.63 (0.07) 
History of diabetes, n (%) 1281 (50.7) 1145 (46.9) 1184 (48.7) 
History of hypertension, n (%) 2075 (82.1) 2014 (82.4) 2036 (83.7) 
History of dyslipidaemia, n (%) 1811 (71.7) 1792 (73.3) 1751 (72.0) 
Family history of premature coronary 
heart disease, n (%) 571 (22.6) 531 (21.7) 557 (22.9) 
Leisure-time physical activity, METs-
min/day 231 (231) 247 (247) 214 (241) 
Total energy intake, kcal/day 2281 (591) 2315 (599) 2216 (590) 
Baseline Mediterranean diet adherence 
scorea 8.7 (2.0) 8.7 (2.0) 8.4 (2.1) 
EVOO, extra virgin olive oil; MET, metabolic equivalent tasks 453 
Values indicate means (standard deviations), unless otherwise stated 454 
 25 
a Based on a 14-item dietary screener (a score of 0 indicates minimum adherence and a 455 
score of 14 indicates maximum adherence). 456 
   457 
458 
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Table 2 Incidence of heart failure during the trial period with active intervention (2003-2010) 459 
by intervention group   460 
 Mediterranean 
diet+EVOO 
(n=2527) 
Mediterranean 
diet+nuts 
(n=2444) 
Control diet 
(n=2432) 
P value 
During the trial intervention 
period (2003-2010) 
   Mediterranean 
diet+EVOO 
vs. Control 
Mediterranean 
diet+nuts vs. 
Control 
Cases (n=94) 29 33 32   
Person-years of follow-up 11737 10279 9664   
Crude rate/1000 person-years 
(95% CI) 
2.5 (1.7-3.5) 3.2 (2.2-4.5) 3.3 (2.3-4.7)   
Hazard ratios (95% CI)       
Crude model* 0.68 (0.41-1.13) 0.92 (0.56-1.49) 1(ref.) 0.139 0.725 
Age- and sex-adjusted model* 0.71 (0.43-1.19) 0.98 (0.60-1.61) 1(ref.) 0.193 0.943 
Multivariate adjusted model 1*(a) 0.77 (0.46-1.28) 1.04 (0.64-1.71) 1(ref.) 0.312 0.864 
Multivariate adjusted model 2*(b) 0.78 (0.46-1.30) 1.07 (0.65-1.76) 1(ref.) 0.336 0.792 
Multivariate adjusted model 3*(c) 0.74 (0.44-1.24) 1.01 (0.61-1.66) 1(ref.) 0.248 0.981 
CI, confidence interval; EVOO, Extra-virgin olive oil; HF, Heart Failure  461 
*All models were stratified according to centre and history of diabetes and used robust 462 
variance estimators.  463 
(a) Adjusted for age, sex, education (four categories), smoking (three categories), waist-to-464 
height ratio (continuous), physical activity (METS-min/d), dyspnea symptoms at baseline 465 
(three categories) and non-AF arrhythmias at baseline. 466 
(b) Adjusted for (a), history of hypertension, history of dyslipidaemia, family history of 467 
premature coronary heart disease and baseline prevalence of atrial fibrillation. 468 
(c) Adjusted for (a), (b) and baseline energy intake (kcal/day). 469 
   470 
471 
 27 
Legends 472 
 473 
Figure 1 Kaplan–Meier estimates of the incidence of heart failure in the total study 474 
population (trial intervention period, 2003-2010) 475 
Footnote to Figure 1:  476 
Hazard ratios were stratified by centre and history of diabetes (Cox model with robust 477 
variance estimators). 478 
  479 
 480 
 481 
 482 
 483 
484 
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Supplementary Appendix 1 485 
Diagnostic criteria for trial endpoint 486 
(Version July, 2005 – Modified December, 2006) 487 
 488 
Heart failure (HF) 489 
Based on the 2005 guidelines of the European Society of Cardiology, an event was 490 
classified as HF if patients had symptoms and/ or signs of HF (frequent breathlessness 491 
or fatigue at rest or during exertion, or ankle swelling) attributable to objective 492 
evidence of cardiac dysfunction at rest (preferably by echocardiography). The clinical 493 
picture may appear suddenly or in a progressive way. 494 
 495 
For a definition of the other cardiovascular endpoints of the PREDIMED trial, we 496 
would like to refer the readers to the following citations: 497 
Myocardial infarction (MI), stroke, cardiovascular (CVD) death:  498 
Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, Gómez-Gracia E, 499 
Ruiz-Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pintó 500 
X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Martínez-González MA. Primary 501 
prevention of cardiovascular disease with a Mediterranean diet. New Engl J Med 502 
2013; 368:1279-1290. 503 
 504 
Atrial fibrillation (AF): 505 
Martínez-González MA, Toledo E, Arós F, Fiol M, Corella D, Salas-Salvadó J, Ros 506 
E, Covas MI, Fernández-Crehuet J, Lapetra J, Muñoz MA, Fitó M, Serra-Majem L, 507 
Pintó X, Lamuela-Raventós RM, Sorlí JV, Babio N, Buil-Cosiales P, Ruiz-Gutierrez 508 
V, Estruch R, Alonso A. Extra-virgin olive oil consumption reduces risk of atrial 509 
 29 
fibrillation: The PREDIMED (Prevención con Dieta Mediterránea) trial. Circulation 510 
2014; 130:18-26. 511 
 512 
Peripheral arterial disease (PAD) 513 
Ruiz-Canela M, Estruch R, Corella D, Salas-Salvadó J, Martínez-González MA. 514 
Association of Mediterranean diet with peripheral artery disease: The PREDIMED 515 
randomized trial. JAMA 2014; 311:415-417.  516 
 517 
 518 
519 
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Supplementary Appendix 2 520 
 521 
 522 
523 
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Supplementary Appendix 3 524 
Table S3 Baseline characteristics of participants who developed heart failure during 525 
the trial period with active intervention (2003-2010) and those who did not  526 
  
Participants who 
developed heart 
failure (n=94) 
Participants who 
did not develop 
heart failure 
(n=7309) 
P value 
Age, years 71.0 (5.9) 66.9 (6.2) <0.001 
Sex, female, n (%) 50 (53.2) 4208 (57.6) 0.390 
Smoking, n (%) 
      Current 11 (11.7) 1027 (14.1) 
0.506 
Education, n (%) 
      University or higher 
      Secondary school 
      Primary school 
      No education 
5 (5.3) 
9 (9.6) 
75 (79.8) 
5 (5.3) 
526 (7.2) 
1107 (15.2) 
5362 (73.4) 
314 (4.3) 
0.124 
Waist-to-height ratio 0.65 (0.06) 0.63 (0.07) 0.006 
BT-pro-BNP, pg/mL 635.9 (314.7) 589.4 (170.6) 0.009 
History of diabetes, n (%) 61 (64.9) 3549 (48.6) 0.002 
History of hypertension, n (%) 81 (86.2) 6044 (82.7) 0.372 
History of dyslipidaemia, n (%) 57 (60.6) 5297 (72.5) 0.010 
Family history of premature coronary 
heart disease, n (%) 18 (19.2) 1641 (22.5) 
0.446 
Leisure-time physical activity, METs-
min/day 187 (184) 231 (240) 
0.076 
 32 
Total energy intake, kcal/day 2344 (716) 2270 (592) 0.230 
Baseline Mediterranean diet adherence 
scorea 8.2 (2.5) 8.6 (2.0) 
0.054 
BT-pro-BNP, B-type natriuretic peptide; EVOO, extra virgin olive oil; MET, metabolic 527 
equivalent tasks 528 
Values indicate means (standard deviations), unless otherwise stated 529 
a Based on a 14-item dietary screener (a score of 0 indicates minimum adherence and a 530 
score of 14 indicates maximum adherence). 531 
  532 
533 
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Supplementary Appendix 4 534 
Table S4 Incidence of heart failure during the trial period with active intervention (2003-535 
2010) and trial period including both the active intervention period and the extended follow-536 
up (2003-2012): both Mediterranean diets combined versus the control diet   537 
 Combined Mediterranean diets 
(n=4971) 
Control diet 
(n=2432)  
P value*  
During the trial intervention 
period (2003-2010)  
   
Cases (n=94) 62 32  
Person-years of follow-up 22016 9664  
Crude rate/1000 person-years 
(95% CI) 
2.8 (2.2-3.6) 3.3 (2.3-4.7)  
Hazard ratios (95% CI)     
Crude model* 0.79 (0.51-1.22) 1 (ref.) 0.283 
Age- and sex-adjusted model* 0.84 (0.54-1.29) 1 (ref.) 0.415 
Multivariate adjusted model 1* (a) 0.89 (0.58-1.38) 1 (ref.) 0.616 
Multivariate adjusted model 2* (b) 0.91 (0.59-1.41) 1 (ref.) 0.673 
Multivariate adjusted model 3* (c) 0.86 (0.55-1.34) 1 (ref.) 0.504 
Trial intervention period plus 
extended follow-up (2003-2012) 
   
Cases (n=141) 92 49  
Person-years of follow-up 29326 13940  
Crude rate/1000 person-years 
(95% CI) 
3.1 (2.5-3.8) 3.5 (2.6-4.6)  
Hazard ratios (95% CI)     
Crude model* 0.84 (0.59-1.19) 1 (ref.) 0.316 
Age- and sex-adjusted model* 0.88 (0.62-1.25) 1 (ref.) 0.476 
Multivariate adjusted model 1* (a) 0.94 (0.66-1.34) 1 (ref.) 0.723 
Multivariate adjusted model 2* (b) 0.96 (0.67-1.36) 1 (ref.) 0.801 
 34 
Multivariate adjusted model 3* (c) 0.94 (0.66-1.34) 1 (ref.) 0.725 
CI, confidence interval; HF, Heart Failure  538 
*All models were stratified according to recruiting centre and history of diabetes and used 539 
robust variance estimators. All P values were calculated using Cox proportional-hazards 540 
models with robust variance estimators. 541 
(a) Adjusted for age, sex, education (University or higher, secondary school, primary school 542 
or no education), smoking (never, current or former smoker), waist-to-height ratio 543 
(continuous), physical activity (METS-min/d), dyspnea symptoms at baseline (no symptoms, 544 
symptoms after high effort and symptoms after moderate/minimal effort or symptoms, not 545 
specified) and non-AF arrhythmias at baseline. 546 
(b) Adjusted for the above, in addition to history of hypertension, history of dyslipidaemia, 547 
family history of premature coronary heart disease and baseline prevalence of atrial 548 
fibrillation. 549 
(c) Adjusted for (a) and (b), in addition to baseline energy intake (kcal/day). 550 
 551 
552 
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Supplementary Appendix 5 553 
Table S5 Subgroup analyses of the incidence of heart failure during the trial period with 554 
active intervention (2003-2010) by intervention group   555 
 HF events/Total Hazard Ratios (95% CI) P value for 
interaction* 
 MedDiet, 
EVOO 
MedDiet, 
nuts 
Control MedDiet, 
EVOO 
MedDiet, nuts Combined 
Mediterranean 
diets 
Sex 
   Male 
   Female 
 
12/1043 
17/1484 
 
20/1125 
13/1319 
 
12/977 
20/1455 
 
0.86 (0.38-1.96) 
0.68 (0.34-1.34) 
 
1.40 (0.67-2.92) 
0.80 (0.39-1.67) 
 
0.490 
Age, years  
   <67 
   ≥ 67 
 
10/1256 
19/1271 
 
7/1235 
26/1209 
 
8/1117 
24/1315 
 
0.86 (0.33-2.24) 
0.71 (0.38-1.33) 
 
0.62 (0.21-1.79) 
1.18 (0.66-2.09) 
 
0.130 
Smoking 
   Never 
   Ever 
 
19/1565 
10/962 
 
16/1458 
17/986 
 
21/1517 
11/915 
 
0.75 (0.39-1.42) 
0.74 (0.31-1.78) 
 
0.81 (0.41-1.60) 
1.34 (0.61-2.94) 
 
0.480 
History of diabetes 
   No  
   Yes 
 
9/1246 
20/1281 
 
11/1299 
22/1145 
 
13/1248 
19/1184 
 
0.48 (0.20-1.17) 
0.82 (0.43-1.56) 
 
0.66 (0.29-1.51) 
1.21 (0.64-2.27) 
 
0.010 
History of hypertension 
   No 
   Yes 
 
3/452 
26/2075 
 
5/430 
28/2014 
 
5/396 
27/2036 
 
0.63 (0.13-3.05) 
0.75 (0.43-1.32) 
 
1.29 (0.29-5.67) 
1.02 (0.60-1.76) 
 
0.650 
History of dyslipidaemia 
   No 
   Yes 
 
11/716 
18/1811 
 
13/652 
20/1792 
 
13/681 
19/1751 
 
0.71 (0.31-1.63) 
0.69 (0.36-1.36) 
 
1.02 (0.46-2.27) 
0.92 (0.48-1.77) 
 
0.990 
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Family history of 
premature CHD 
   No 
   Yes 
 
 
26/1956 
3/571 
 
 
26/1913 
7/531 
 
 
24/1875 
8/557 
 
 
0.91 (0.51-1.61) 
0.37 (0.09-1.52) 
 
 
1.06 (0.60-1.89) 
1.09 (0.36-3.30) 
 
 
0.330 
History of AF 
   No 
   Yes 
 
28/2510 
1/17 
 
32/2423 
1/21 
 
32/2409 
0/23 
 
0.71 (0.42-1.19) 
- 
 
0.99 (0.60-1.64) 
- 
 
0.190 
Body mass index,  kg/m2 
   <30 
   ≥30 
 
13/1335 
16/1192 
 
18/1353 
15/1091 
 
16/1233 
16/1199 
 
0.67 (0.32-1.41) 
0.85 (0.41-1.77) 
 
1.04 (0.52-2.09) 
1.04 (0.50-2.18) 
 
0.610 
Waist-to-height ratio 
  <0.63 
  ≥ 0.63 
 
9/1366 
20/1161 
 
20/1369 
13/1075 
 
12/1272 
20/1160 
 
0.62 (0.25-1.52) 
0.70 (0.36-1.34) 
 
1.75 (0.83-3.69) 
0.57 (0.27-1.19) 
 
0.040 
Baseline score for 
MedDiet adherence 
  <9 (low) 
  ≥ 9 (high) 
 
 
19/1113 
10/1414 
 
 
13/1055 
20/1389 
 
 
20/1250 
12/1182 
 
 
1.00 (0.52-1.93) 
0.59 (0.25-1.39) 
 
 
0.75 (0.36-1.54) 
1.38 (0.66-2.89) 
 
 
0.040 
AF, atrial fibrillation; CHD, coronary heart disease; CI, confidence interval; EVOO, Extra-556 
virgin olive oil; HF, Heart Failure; MedDiet, Mediterranean diet 557 
All models were stratified according to recruiting centre and history of diabetes (apart from 558 
when history of diabetes was examined as a subgroup) and used robust variance estimators. 559 
All models were adjusted for age, sex, education (University or higher, secondary school, 560 
primary school or no education), smoking (never, current or former smoker), waist-to-height 561 
ratio (continuous), physical activity (METS-min/d), dyspnea symptoms at baseline (no 562 
symptoms, symptoms after high effort and symptoms after moderate/minimal effort or 563 
symptoms, not specified), non-AF arrhythmias at baseline, history of hypertension, history of 564 
dyslipidaemia, family history of premature coronary heart disease, baseline prevalence of 565 
 37 
atrial fibrillation and baseline energy intake (kcal/day).  566 
* P values were calculated using Cox proportional-hazards models with robust variance estimators. 567 
Interactions for both MedDiet groups were assessed by a likelihood ratio test with 2 degrees of 568 
freedom: grouping variable x (MedDiet with EVOO) and grouping variable x (MedDiet with nuts). 569 
   570 
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Supplementary Appendix 6 572 
Table S6 Incidence of heart failure during the trial period including both the active 573 
intervention period and the extended follow-up (2003-2012) by intervention group   574 
 Mediterranean 
diet+EVOO 
(n=2527) 
Mediterranean 
diet+nuts 
(n=2444) 
Control diet 
(n=2432) 
P value 
Trial intervention period plus 
extended follow-up (2003-2012)    
  
Cases (n=141) 43 49 49   
Person-years of follow-up 15261 14064 13940   
Crude rate/1000 person-years 
(95% CI) 
2.8 (2.0-3.8) 3.5 (2.6-4.6) 3.5 (2.6-4.6)   
Hazard ratios (95% CI)       
Crude model* 0.71 (0.47-1.07) 0.99 (0.67-1.48) 1(ref.) 0.100 0.970 
Age- and sex-adjusted model* 0.73 (0.49-1.11) 1.06 (0.71-1.58) 1(ref.) 0.146 0.771 
Multivariate adjusted model 1*(a) 0.79 (0.52-1.19) 1.13 (0.75-1.69) 1(ref.) 0.260 0.562 
Multivariate adjusted model 2*(b) 0.80 (0.53-1.21) 1.16 (0.77-1.73) 1(ref.) 0.290 0.485 
Multivariate adjusted model 3*(c) 0.78 (0.52-1.19) 1.14 (0.76-1.70) 1(ref.) 0.252 0.540 
CI, confidence interval; EVOO, Extra-virgin olive oil; HF, Heart Failure  575 
*All models were stratified according to centre and history of diabetes and used robust 576 
variance estimators.  577 
(a) Adjusted for age, sex, education (four categories), smoking (three categories), waist-to-578 
height ratio (continuous), physical activity (METS-min/d), dyspnea symptoms at baseline 579 
(three categories) and non-AF arrhythmias at baseline. 580 
(b) Adjusted for (a), history of hypertension, history of dyslipidaemia, family history of 581 
premature coronary heart disease and baseline prevalence of atrial fibrillation. 582 
(c) Adjusted for (a), (b) and baseline energy intake (kcal/day). 583 
584 
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Figure S7 Exploratory meta-analysis of observational cohort studies examining the 586 
association between Mediterranean diet adherence and heart failure incidence 587 
 588 
 589 
A random effects model was used. The estimates of each study included in the meta-analysis were 590 
transformed to capture the effect on the risk of HF (or mortality in patients with HF) for an additional 591 
+2 point increment in a 0 to 9 score of adherence to the MedDiet.  592 
The two studies by Tektonidis et al [Tektonidis et al (2015) A Mediterranean diet and risk of 593 
myocardial infarction, heart failure and stroke: A population-based cohort study. Atherosclerosis 594 
243:93-98 and Tektonidis et al (2016) Adherence to a Mediterranean diet is associated with reduced 595 
risk of heart failure in men. Eur J Heart Fail 18:253-259] were excluded because Larsson [Larsson et 596 
al (2016) Healthy lifestyle and risk of heart failure: results from 2 prospective cohort studies. Circ 597 
Heart Fail 9:e002855] analysed the same cohorts, but using a slightly larger sample size in updated 598 
databases. 599 
600 
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Figure S8 Factors independently associated with heart failure  602 
 603 
 604 
Cut-off values indicate medians, unless otherwise stated. 605 
*All models were stratified by centre, intervention group and history of diabetes (apart from when 606 
history of diabetes was examined as a predictor) and used robust variance estimators. All models were 607 
adjusted for age, sex, education (four categories), smoking (three categories), waist-to-height ratio 608 
(continuous), physical activity (METS-min/d), dyspnea symptoms at baseline (no symptoms, 609 
symptoms after high effort and symptoms after moderate/minimal effort or symptoms, not specified), 610 
non-AF arrhythmias at baseline, history of hypertension, history of dyslipidaemia, family history of 611 
premature coronary heart disease, baseline prevalence of atrial fibrillation and baseline energy intake 612 
(kcal/day). Confidence intervals were estimated using Cox proportional-hazards models with robust 613 
variance estimators. 614 
615 
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Table S9 Incidence of total cardiovascular events (stroke, myocardial infarction, 617 
cardiovascular death, heart failure, atrial fibrillation or peripheral arterial disease) during the 618 
trial period with active intervention (2003-2010) by intervention group  619 
 Mediterranean 
diet+EVOO 
(n=2510) 
Mediterranean 
diet+nuts 
(n=2423) 
Control diet 
(n=2409) 
P value 
    Mediterranean 
diet+EVOO vs. 
Control 
Mediterranean 
diet+nuts vs. 
Control 
Cases (n=634) 196 202 236   
Person-years of follow-up 11479 10038 9397   
Crude rate/1000 person-years (95% CI) 1.7 (1.5-2.0) 2.0 (1.7-2.3) 2.5 (2.2-2.8)   
Hazard ratios (95% CI)       
Crude model† 0.62 (0.51-0.75) 0.77 (0.63-0.93) 1(ref.) <0.001 0.006 
Age- and sex-adjusted model†  0.63 (0.52-0.76) 0.76 (0.63-0.92) 1(ref.) <0.001 0.005 
Multivariate adjusted model 1†(a) 0.64 (0.53-0.78) 0.78 (0.64-0.94) 1(ref.) <0.001 0.011 
Multivariate adjusted model 2†(b) 0.65 (0.53-0.78) 0.79 (0.66-0.96) 1(ref.) <0.001 0.019 
Multivariate adjusted model 3†(c) 0.65 (0.53-0.78) 0.79 (0.65-0.96) 1(ref.) <0.001 0.018 
CI, confidence interval; CVD, cardiovascular disease; EVOO, Extra-virgin olive oil 620 
† All models were stratified according to centre and history of diabetes. 621 
(a) Adjusted for age, sex, education (four categories), smoking (three categories), waist-to-622 
height ratio (continuous), physical activity (METS-min/d), dyspnea symptoms at baseline 623 
(three categories) and non-AF arrhythmias at baseline.  624 
(b) Adjusted for (a), family history of premature coronary heart disease, history of 625 
dyslipidaemia and history of hypertension.  626 
(c) Adjusted for (b) and baseline energy intake (kcal/day).   627 
628 
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Figure S10 Kaplan–Meier estimates of total cardiovascular events (stroke, myocardial 630 
infarction, cardiovascular death, heart failure, atrial fibrillation or peripheral arterial disease) 631 
in the total study population (trial intervention period, 2003-2010)  632 
 633 
 634 
Hazard ratios were stratified by centre and sex (Cox model with robust variance estimators). 635 
 636 
   637 
 638 
 639 
